D-penicillamine in early rheumatoid arthritis. 1997

A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari

UI MeSH Term Description Entries
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
January 1986, Indian journal of pediatrics,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
January 1979, Harefuah,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
April 1984, Annals of the rheumatic diseases,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
May 1975, Lancet (London, England),
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
January 1978, Reumatizam,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
January 1981, The Journal of rheumatology. Supplement,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
January 1980, Annals of internal medicine,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
November 1976, Annals of internal medicine,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
August 1973, British medical journal,
A A Drosos, and P Geogriou, and E N Politi, and P V Voulgari
September 1973, British medical journal,
Copied contents to your clipboard!